17 of 50
Johnson & Johnson
Johnson & Johnson
Top 50 rank: 17
Rank in Pharmaceuticals: 3
(Previous rank: 2)
Overall score: 6.72
Why it's admired
J&J has been in better health. The company maintains an impressive portfolio of products and brands that millions of people around the world rely on for their everyday skin care, baby care and first aid, but it had a rough year.

After more than half a dozen recalls of nonprescription drugs, including Tylenol, Benadryl and Motrin, CEO William C. Weldon apologized to lawmakers at a Congressional hearing in September. Its DePuy Orthopaedics unit also recalled two hip implant systems in August.

Yet J&J maintained its position as a multibillion-dollar pharmaceutical company.

In a recent earnings report, Weldon said: "Although 2010 was a challenging year, the business continued to deliver earnings growth, while investing in the future and emerging a stronger organization." --T.M.

Should Johnson & Johnson be admired, or what?
Johnson & Johnson stats
Nine key attributes of reputation Industry rank
Innovation 9
People management 3
Use of corporate assets 1
Social responsibility 1
Quality of management 6
Financial soundness 1
Long-term investment 1
Quality of products/services 8
Global competitiveness 3
From the March 21, 2011 issue
1 Johnson & Johnson Plaza
New Brunswick, NJ 8933
Show: Top 50 | All Most Admired: The Americas | Europe | Asia/Australia
Find companies you most admire
 Innovation  Quality of management
 People management  Financial soundness
 Use of corporate assets  Long-term investment
 Social responsibility  Product/services quality
 Global competitiveness  

The Most Admired list is the definitive report card on corporate reputations. Our survey partners at Hay Group start with about 1,400 companies... More
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.